Hamed Mataria, MD
Pulmonary Disease · Chicago Ridge, ILNPI 1285845818
Payments from drug & device makers
Across 261 payments — averaging $55.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$9K
- GSK$2K
- AstraZeneca$549
- Jazz Pharmaceuticals Inc.$445
- Sanofi$346
- Actelion Pharmaceuticals US, Inc.$271
- plus $2K from 23 others
What the payments were for
- Travel & lodging$2,03414%
- Food & beverage$5,15036%
- Education$7,17950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 13 | $9,181 |
| GSK | 108 | $1,615 |
| AstraZeneca | 22 | $549 |
| Jazz Pharmaceuticals Inc. | 7 | $445 |
| Sanofi | 11 | $346 |
| Actelion Pharmaceuticals US, Inc. | 9 | $271 |
| Boehringer Ingelheim | 10 | $245 |
| Pulmonx Corporation | 2 | $228 |
| Insmed, Inc. | 10 | $198 |
| Regeneron Healthcare Solutions, Inc. | 7 | $195 |
| Grifols USA, LLC | 6 | $119 |
| Philips North America LLC | 5 | $97 |
| Electromed, Inc. | 9 | $95 |
| Mylan Specialty L.p. | 5 | $88 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $85 |
| Inogen, Inc. | 6 | $82 |
| Avadel CNS Pharmaceuticals, LLC | 4 | $79 |
| Amgen | 4 | $78 |
| United Therapeutics Corporation | 4 | $73 |
| Merck | 4 | $71 |
| Baxter Healthcare | 2 | $53 |
| Genentech USA, Inc. | 2 | $30 |
| Circassia Inc. | 2 | $27 |
| Advanced Respiratory, Inc | 1 | $27 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Mayne Pharma Commercial LLC | 1 | $17 |
| Chiesi USA, Inc. | 1 | $16 |
| Pfizer | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$9,107
- XYWAV$150
- CHARTIS CATHETER$149
- ZEPHYR DELIVERY CATHETER$149
- ZEPHYR ENDOBRONCHIAL VALVE$149
- PULMONX CHARTIS TABLET CONSOLE$149
- BREZTRI$135
- NUCALA$125
- TEZSPIRE$125
- DUPIXENT$122
How this compares
$14,363 in reported general payments places this provider in the 80th percentile of 539 pulmonary disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 72 | $939,742 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 339 | $269,007 |
| NucalaMepolizumab | 11 | $40,335 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 58 | $36,248 |
| Spiriva RespimatTiotropium Bromide | 45 | $32,971 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 46 | $25,465 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $22,561 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $18,921 |
| Incruse ElliptaUmeclidinium Bromide | 42 | $15,123 |
| Pirfenidone | 17 | $13,375 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 189 | $6,870 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $5,897 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 31 | $4,354 |
| Tiotropium Bromide | 12 | $3,222 |
| Ventolin HfaAlbuterol Sulfate | 30 | $2,522 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $245 | $998,177163 claims |
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,615 | $379,634487 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $549 | $28,45763 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 539 pulmonary disease providers in Illinois.
Other pulmonary disease in Chicago Ridge
- Essam MekhaielChicago Ridge$224K
- Mohammad OmariChicago Ridge$195K
- Douglas HogarthChicago$3.1M
- Manu JainChicago$1.9M
- Momen WahidiChicago$1.2M
- Shashi BellamEvanston$1.2M
- Marilyn GlassbergMaywood$1000K
- Steven WhiteChicago$989K
- Ravi KalhanChicago$831K
- Patrick WhittenPeoria$812K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.